{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:34:48Z","timestamp":1792715688617,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jns.2019.116576","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T21:05:56Z","timestamp":1573247156000},"page":"116576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Antiganglioside antibodies in neurological diseases"],"prefix":"10.1016","volume":"408","author":[{"given":"Pitchaya","family":"Wanleenuwat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Iwanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kozubski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2019.116576_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5650\/jos.60.537","article-title":"Structures, biosynthesis, and functions of gangliosides\u2014an overview","volume":"60","author":"Yu","year":"2011","journal-title":"J. Oleo Sci."},{"key":"10.1016\/j.jns.2019.116576_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/35036052","article-title":"Lipid rafts and signal transduction","volume":"1","author":"Simons","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jns.2019.116576_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-62817-2_1","article-title":"What is neural plasticity?","volume":"1015","author":"von Bernhardi","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jns.2019.116576_bb0020","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1113\/jphysiol.2009.171702","article-title":"Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction","volume":"587","author":"Plomp","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.jns.2019.116576_bb0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/glycob\/cwp027","article-title":"Antiganglioside antibodies and their pathophysiological effects on Guillain\u2013Barr\u00e9 syndrome and related disorders\u2014a review","volume":"19","author":"Kaida","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.jns.2019.116576_bb0030","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00415-018-9109-z","article-title":"Anti-ganglioside antibody-associated acute unilateral peripheral vestibulopathy","volume":"266","author":"Lee","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0040","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/jnnp.2003.032193","article-title":"Antiganglioside antibodies in paraneoplastic peripheral neuropathies","volume":"75","author":"Antoine","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0045","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/jnr.23411","article-title":"Pathogenic role of ganglioside metabolism in neurodegenerative diseases","volume":"92","author":"Ariga","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jns.2019.116576_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1473-3099(01)00019-6","article-title":"Infectious origins of, and molecular mimicry in, Guillain-Barr\u00e9 and fisher syndromes","volume":"1","author":"Yuki","year":"2001","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jns.2019.116576_bb0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2005.11.013","article-title":"Anti-ganglioside antibodies in coeliac disease with neurological disorders","volume":"38","author":"Volta","year":"2006","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jns.2019.116576_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/bs.pmbts.2018.03.001","article-title":"Gangliosides in axon stability and regeneration","volume":"156","author":"Lopez","year":"2018","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jns.2019.116576_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/JND-150078","article-title":"Diagnostic utility of auto antibodies in inflammatory nerve disorders","volume":"2","author":"Emilien","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.jns.2019.116576_bb0070","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/brain\/awq260","article-title":"Conduction block in acute motor axonal neuropathy","volume":"133","author":"Kokubun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116576_bb0075","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2019.116576_bb0080","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/brain\/awq119","article-title":"Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice","volume":"133","author":"McGonigal","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116576_bb0085","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jnnp-2017-317192","article-title":"Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground","volume":"89","author":"Uncini","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0090","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.clinph.2013.03.025","article-title":"Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies","volume":"124","author":"Uncini","year":"2013","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.jns.2019.116576_bb0095","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1093\/brain\/awf258","article-title":"Localization of major gangliosides in the PNS: implications for immune neuropathies","volume":"125","author":"Gong","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116576_bb0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.mayocp.2016.12.002","article-title":"Guillain-Barr\u00e9 syndrome","volume":"92","author":"Wijdicks","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jns.2019.116576_bb0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ncl.2013.01.005","article-title":"Guillain-Barr\u00e9 syndrome and variants","volume":"31","author":"Dimachkie","year":"2013","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2019.116576_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/1673-5374.125337","article-title":"Critical illness polyneuropathy and myopathy: a systematic review","volume":"9","author":"Zhou","year":"2014","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jns.2019.116576_bb0115","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4103\/0028-3886.241402","article-title":"Antibodies to Zika virus, campylobacter jejuni and gangliosides in Guillain-Barre syndrome: a prospective single-center study from southern India","volume":"66","author":"Baskar","year":"2018","journal-title":"Neurol. India"},{"key":"10.1016\/j.jns.2019.116576_bb0120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4103\/neuroindia.NI_1226_15","article-title":"Anti-ganglioside antibodies profile in Guillain-Barr\u00e9 syndrome: correlation with clinical features, electrophysiological pattern, and outcome","volume":"65","author":"Naik","year":"2017","journal-title":"Neurol. India"},{"key":"10.1016\/j.jns.2019.116576_bb0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6","article-title":"Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr\u00e9 syndrome","volume":"45","author":"Ho","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0130","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mus.25266","article-title":"Anti-ganglioside antibodies in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients","volume":"55","author":"Fan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2019.116576_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/jnnp-2011-300309","article-title":"Antiganglioside antibodies are associated with axonal Guillain-Barr\u00e9 syndrome: a Japanese-Italian collaborative study","volume":"83","author":"Sekiguchi","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0140","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0165-5728(00)00461-6","article-title":"Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies","volume":"114","author":"Cavanna","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2019.116576_bb0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3988\/jcn.2018.14.3.401","article-title":"Clinical heterogeneity of anti-GM2-ganglioside-antibody syndrome","volume":"14","author":"Kim","year":"2018","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncpneuro0001","article-title":"Ganglioside complexes: new autoantibody targets in Guillain-Barr\u00e9 syndromes","volume":"1","author":"Willison","year":"2005","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0155","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1471-4159.2010.07029.x","article-title":"Antibodies against ganglioside complexes in Guillain-Barr\u00e9 syndrome and related disorders","volume":"116","author":"Kusunoki","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2019.116576_bb0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ana.20222","article-title":"Ganglioside complexes as new target antigens in Guillain-Barr\u00e9 syndrome","volume":"56","author":"Kaida","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jneuroim.2006.09.013","article-title":"Anti-ganglioside complex antibodies associated with severe disability in GBS","volume":"182","author":"Kaida","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2019.116576_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2012-302312","article-title":"Biology of the blood\u2013nerve barrier and its alteration in immune mediated neuropathies","volume":"84","author":"Kanda","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1468-1331.2006.01161.x","article-title":"Anti-ganglioside antibodies and elevated CSF IgG levels in Guillain-Barr\u00e9 syndrome","volume":"13","author":"Mat\u00e0","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0180","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1523\/JNEUROSCI.4926-14.2015","article-title":"Anti-ganglioside antibodies induce nodal and axonal injury via Fc\u03b3 receptor-mediated inflammation","volume":"35","author":"He","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2019.116576_bb0185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3988\/jcn.2014.10.2.94","article-title":"Prevalence of anti-ganglioside antibodies and their clinical correlates with Guillain-Barr\u00e9 syndrome in Korea: a Nationwide multicenter study","volume":"10","author":"Kim","year":"2014","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0190","first-page":"589","article-title":"Antiganglioside autoantibody profiles in Guillain-Barr\u00e9 syndrome","volume":"60","author":"Caudie","year":"2002","journal-title":"Ann. Biol. Clin. (Paris)"},{"key":"10.1016\/j.jns.2019.116576_bb0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-510X(99)00180-X","article-title":"Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile","volume":"168","author":"Yuki","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2019.116576_bb0200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4103\/0028-3886.86549","article-title":"Clinical, electrophysiological subtypes and antiganglioside antibodies in childhood Guillain-Barr\u00e9 syndrome","volume":"59","author":"Kannan","year":"2011","journal-title":"Neurol. India"},{"key":"10.1016\/j.jns.2019.116576_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124004","article-title":"Complex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies","volume":"10","author":"Koga","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2019.116576_bb0210","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/039463200902200220","article-title":"Antibodies to ganglioside complexes in Guillain-Barr\u00e9 syndrome: clinical correlates, fine specificity and complement activation","volume":"22","author":"Notturno","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.jns.2019.116576_bb0215","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/IAI.72.4.2148-2151.2004","article-title":"Normally occurring human anti-GM1 immunoglobulin M antibodies and the immune response to bacteria","volume":"72","author":"Alaniz","year":"2004","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jns.2019.116576_bb0220","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1023\/A:1020232318647","article-title":"The origin of anti-GM1 antibodies in neuropathies: the \u201cbinding site drift\u201d hypothesis","volume":"27","author":"Lopez","year":"2002","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jns.2019.116576_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/srep19901","article-title":"Individual restriction of fine specificity variability in anti-GM1 IgG antibodies associated with Guillain-Barr\u00e9 syndrome","volume":"6","author":"Lardone","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2019.116576_bb0230","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/aje\/153.6.610","article-title":"Incidence of Guillain-Barr\u00e9 syndrome following infection with campylobacter jejuni","volume":"153","author":"McCarthy","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jns.2019.116576_bb0235","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp-2012-302824","article-title":"Bickerstaff brainstem encephalitis and fisher syndrome: anti-GQ1b antibody syndrome","volume":"84","author":"Shahrizaila","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0240","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp-2012-304306","article-title":"Blood-brain barrier destruction determines fisher\/Bickerstaff clinical phenotypes: an in vitro study","volume":"84","author":"Saito","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0245","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/brain\/124.5.893","article-title":"Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal","volume":"124","author":"O\u2019Hanlon","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116576_bb0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12883-018-1104-6","article-title":"Miller fisher syndrome, Bickerstaff brainstem encephalitis and Guillain-Barr\u00e9 syndrome overlap with persistent non-demyelinating conduction blocks: a case report","volume":"18","author":"Puma","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0255","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jocn.2004.09.019","article-title":"Cerebellar ataxia and acute motor axonal neuropathy associated with anti GD1b and anti GM1 antibodies","volume":"12","author":"Bae","year":"2005","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2019.116576_bb0260","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00415-014-7388-6","article-title":"GD1b-specific antibodies may bind to complex of GQ1b and GM1, causing ataxia","volume":"261","author":"Yuki","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0265","doi-asserted-by":"crossref","first-page":"740","DOI":"10.5535\/arm.2013.37.5.740","article-title":"Multiple cranial neuropathies without limb involvements: Guillain-Barre syndrome variant?","volume":"37","author":"Yu","year":"2013","journal-title":"Ann. Rehabil. Med."},{"key":"10.1016\/j.jns.2019.116576_bb0270","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/jnnp.2007.142950","article-title":"Ganglioside complexes containing GQ1b as targets in miller fisher and Guillain-Barre syndromes","volume":"79","author":"Kanzaki","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0275","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp.72.6.767","article-title":"Anti-GT1a IgG in Guillain-Barr\u00e9 syndrome","volume":"72","author":"Koga","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0280","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/brain\/aww056","article-title":"Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis","volume":"139","author":"Cunningham","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116576_bb0285","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aww078","article-title":"Neuronal endocytosis of anti-ganglioside antibodies: implications for Guillain-Barr\u00e9 syndrome","volume":"139","author":"van Doorn","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jns.2019.116576_bb0290","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/jnnp.70.1.50","article-title":"Anti-GQ1b IgG antibody syndrome: clinical and immunological range","volume":"70","author":"Odaka","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13760-019-01093-8","article-title":"Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients","volume":"119","author":"de Bruyn","year":"2019","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2019.116576_bb0300","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s00415-015-7806-4","article-title":"Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barr\u00e9 syndrome and its variants","volume":"262","author":"Koga","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0305","article-title":"Role of Anti-ganglioside Antibodies in the Diagnosis of Guillain-Barr\u00e9 Syndrome as an Alternate Investigation","volume":"11","author":"Saeed","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jns.2019.116576_bb0310","first-page":"567","article-title":"Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment","volume":"10","author":"Lawson","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jns.2019.116576_bb0315","first-page":"1","article-title":"Human immune globulin infusion in the management of multifocal motor neuropathy","volume":"6","author":"Jovanovich","year":"2016","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.jns.2019.116576_bb0320","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ana.410370405","article-title":"Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers","volume":"37","author":"Takigawa","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0325","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000119","article-title":"Complement activity is associated with disease severity in multifocal motor neuropathy","volume":"2","author":"Vlam","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2019.116576_bb0330","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/j.1471-4159.1992.tb11018.x","article-title":"Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina","volume":"59","author":"Ogawa-Goto","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2019.116576_bb0335","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JND-150080","article-title":"The diagnostic utility of determining anti-GM1: GalC complex antibodies in multifocal motor neuropathy: a validation study","volume":"2","author":"Galban-Horcajo","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.jns.2019.116576_bb0340","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archneur.60.1.42","article-title":"Antiganglioside antibodies in multifocal acquired sensory and motor neuropathy","volume":"60","author":"Alaedini","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2019.116576_bb0345","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0350","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp-2012-303440","article-title":"Clinical features of CIDP with LM1-associated antibodies","volume":"84","author":"Kuwahara","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-510X(92)90217-9","article-title":"Antibodies to acidic glycolipids in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"107","author":"Ilyas","year":"1992","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2019.116576_bb0360","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/CPJ.0000000000000331","article-title":"Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib","volume":"7","author":"Compter","year":"2017","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jns.2019.116576_bb0365","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/jnnp.74.4.507","article-title":"Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma","volume":"74","author":"Kloos","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.116576_bb0370","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2169\/internalmedicine.54.4451","article-title":"Immune-mediated neuropathy with anti-disialosyl IgM antibodies in diffuse large B-cell lymphoma: a case report and literature review","volume":"54","author":"Shihashi","year":"2015","journal-title":"Intern. Med."},{"key":"10.1016\/j.jns.2019.116576_bb0375","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-03-537506","article-title":"Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas","volume":"123","author":"Graus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jns.2019.116576_bb0380","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2169\/internalmedicine.0667-17","article-title":"Subacute sensorimotor neuropathy accompanied by anti-ganglioside GM1 antibody in a patient with lung cancer","volume":"57","author":"Kanaji","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.jns.2019.116576_bb0385","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.4-041","article-title":"Elevated antiganglioside antibodies in a case of paraneoplastic neuromuscular junction disorder (P5.4\u2013041)","volume":"92","author":"Jazebi","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2019.116576_bb0390","doi-asserted-by":"crossref","first-page":"e1085","DOI":"10.1212\/WNL.0000000000008107","article-title":"Acute vestibular syndrome associated with anti-GQ1b antibody","volume":"93","author":"Lee","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2019.116576_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125339","article-title":"Anti-ganglioside antibodies in amyotrophic lateral sclerosis revisited","volume":"10","author":"Kollewe","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2019.116576_bb0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-510X(88)90054-8","article-title":"Combined features of myasthenia gravis and Eaton-Lambert syndrome: anti-ganglioside antibodies in serum","volume":"87","author":"Kusunoki","year":"1988","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2019.116576_bb0405","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0967-5868(02)00270-9","article-title":"Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis","volume":"10","author":"Pender","year":"2003","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2019.116576_bb0410","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1134\/S0362119717080023","article-title":"Antibodies against myelin lipids in multiple sclerosis","volume":"43","author":"Ivanova","year":"2017","journal-title":"Hum. Physiol."},{"key":"10.1016\/j.jns.2019.116576_bb0415","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1528-1157.1996.tb00527.x","article-title":"Cryptogenic partial epilepsies with anti-GM1 antibodies: a new form of immune-mediated epilepsy?","volume":"37","author":"Bartolomei","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2019.116576_bb0420","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/1533317514534953","article-title":"Antibodies against gangliosides in patients with dementia","volume":"29","author":"Hatzifilippou","year":"2014","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"key":"10.1016\/j.jns.2019.116576_bb0425","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbapap.2018.07.004","article-title":"Ganglioside lipids accelerate \u03b1-synuclein amyloid formation","volume":"1866","author":"Gaspar","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jns.2019.116576_bb0430","doi-asserted-by":"crossref","DOI":"10.4172\/2376-0281.1000159","article-title":"High levels of anti-ganglioside antibodies in patients with Parkinson?S disease associated with cognitive decline","volume":"2","author":"Arnaoutoglou","year":"2015","journal-title":"Int. J. Neurorehabil. Eng."},{"key":"10.1016\/j.jns.2019.116576_bb0435","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1034\/j.1600-0404.2002.01240.x","article-title":"Anti-GM1 ganglioside antibodies in Parkinson\u2019s disease","volume":"106","author":"Zappia","year":"2002","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2019.116576_bb0440","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0304-3940(88)90577-0","article-title":"Antibodies to ganglioside GM1 in patients with Alzheimer\u2019s disease","volume":"86","author":"Chapman","year":"1988","journal-title":"Neurosci. Lett."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19323408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19323408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:49:21Z","timestamp":1758383361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X19323408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":88,"alternative-id":["S0022510X19323408"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2019.116576","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiganglioside antibodies in neurological diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2019.116576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116576"}}